MedWatch

Finnish investor looks for Nordic investors in its new life science & health fund

Two Finnish foundations are among the seed investors of a new life science fund that aims to return at least 250 percent. ”We will now start negotiations with international investors,” says Pekka Simula, partner at Innovestor. The new fund’s management team hopes to replicate what other Nordic life science funds have achieved.

Minna Koistinaho and Pekka Simula, partners at Innovestor | Photo: Innovestor PR.

Finnish venture capital firm Innovestor has launched a new life science and health fund focusing on early stage opportunities in the Nordic and Baltic countries.

Pekka Simula, partner at Innovestor, says to AMWatch the fund is interested particularly in developing treatment for rare diseases and has already screened some 200 companies. The fund’s first investment, however, will most likely be published in Q2.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs